Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify

Executive Summary

Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.

You may also be interested in...



Alkermes Sees Payer Savings Opportunity With Aristada Approval

Long-acting injectable aripiprazole lauroxil cleared six weeks late, but Alkermes is happy with label's flexibility on dosing, saying product will be differentiated from Abilify Maintena.

Otsuka Seeks First Approval For Drug Tablet With Ingestible Sensor

The pharma firm, looking to counter generic competition, is partnering with Proteus Digital Health on a first-of-a-kind FDA submission for a combination product of antipsychotic drug Abilify embedded with an ingestible sensor to measure adherence and physiologic response.

Digital Age: Otsuka Sets Sights On Abilify Combo Tablet With Sensor

First-of-its-kind NDA is for a combination product of Abilify embedded with an ingestible sensor to measure adherence and physiologic response. Otsuka sees opportunities to extend brand facing generic competition and for combo approach with future medicines too.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel